Vaginal Estrogen for Menopause: What It Does, and What It Doesn't

Vaginal estrogen treats genitourinary syndrome of menopause (GSM), the umbrella term adopted in 2014 to replace the older and narrower "vulvovaginal atrophy." The name changed because clinicians realized the condition is not just vaginal. Estrogen receptors are dense in the vagina, vulva, urethra and bladder trigone, and when estrogen falls, all of that tissue changes together.

GSM symptoms include:

• •Vaginal dryness, burning, or irritation
• •Pain with intercourse (dyspareunia)
• •Reduced lubrication and elasticity
• •Urinary urgency and frequency
• •Recurrent urinary tract infections
• •Post-void dribbling and discomfort

An estimated 50 to 70 percent of postmenopausal women experience GSM, and the number climbs with time since the final menstrual period. Yet studies consistently find that fewer than a quarter of affected women are being treated. Some never mention it. Many who do are told it is a normal part of aging and offered a lubricant.

Here is what makes GSM different from every other menopause symptom: it does not go away on its own. Hot flashes peak and then decline over an average of seven to ten years. Sleep disruption often improves. GSM is progressive. The tissue continues to thin, the vaginal pH continues to rise, and the microbiome continues to shift away from lactobacilli. Waiting does not help.

If your primary problem is urinary leaking rather than dryness, the picture overlaps but is not identical, and we cover that in [bladder leaks in menopause](/blog/glp1-menopause-bladder-leaks-urinary-incontinence).

The difference is dose and destination. Systemic hormone therapy is designed to raise circulating estrogen levels enough to affect the whole body: brain, bone, blood vessels, skin. Low-dose vaginal estrogen is designed to act on local tissue and stay there.

The numbers make this concrete. A standard transdermal estradiol patch delivers 50 micrograms per day and produces serum estradiol in the 40 to 60 pg/mL range. A 10-microgram vaginal estradiol tablet, used twice weekly after the loading phase, delivers roughly 1.4 milligrams total over an entire month, and serum estradiol in users generally stays under 10 pg/mL, which is within the normal untreated postmenopausal range.

That difference drives three practical consequences:

You do not need a progestogen. With systemic estrogen and an intact uterus, you need a progestogen to protect the endometrium. With low-dose vaginal estrogen, endometrial stimulation has not been demonstrated at standard doses, and neither ACOG nor The Menopause Society recommends adding a progestogen or routine endometrial surveillance.

It does not treat systemic symptoms. Vaginal estrogen will not touch hot flashes, night sweats, sleep, mood or bone loss. If those are your main complaints, you need systemic therapy, and that is a different conversation, covered in [bioidentical vs synthetic HRT](/blog/bioidentical-vs-synthetic-hrt-what-the-difference-means).

The risk profile is different. This is the part that gets lost, and it deserves its own section.

You can use both. Many women on a systemic patch still need local estrogen, because systemic doses are often not sufficient to fully resolve vaginal tissue changes. Combining them is standard practice, not double-dosing.

The best available evidence says yes for the large majority of women, and the warning label on the box overstates the risk.

The most useful dataset comes from the Women's Health Initiative Observational Study. Crandall and colleagues (Menopause, 2018) followed 45,663 postmenopausal women, including roughly 2,000 vaginal estrogen users, over a median of about 7 years. Compared with non-users, vaginal estrogen users showed no increased risk of stroke, coronary heart disease, invasive breast cancer, pulmonary embolism or deep vein thrombosis. Among women with an intact uterus, there was no increased risk of endometrial cancer.

Despite this, every vaginal estrogen product in the United States carries a boxed warning about endometrial cancer, cardiovascular disorders, breast cancer and dementia. That warning is class labeling carried over from systemic hormone therapy trials, principally the WHI's oral conjugated equine estrogen plus medroxyprogesterone arm. It was not generated from studies of vaginal products. Both ACOG and The Menopause Society have formally argued that the warning is not supported by the data for low-dose vaginal preparations and discourages appropriate treatment.

This matters practically. Women read the insert, get frightened, and stop. Clinicians unfamiliar with the distinction decline to prescribe. Meanwhile the untreated condition progresses.

A note on breast cancer survivors: this is genuinely more nuanced. ACOG's position is that nonhormonal options should be tried first, and that if they fail, low-dose vaginal estrogen may be considered in consultation with the patient's oncologist. The main caution is for women on aromatase inhibitors, where even small estrogen increases are theoretically undesirable, and where vaginal DHEA or ospemifene may be preferred. This is a shared-decision conversation, not a blanket prohibition.

For context on how the WHI data is routinely misread in the systemic setting too, see [what the WHI actually found about HRT and breast cancer](/blog/hrt-and-breast-cancer-risk-what-the-whi-data-actually-shows).

There are five main options in the US, and the choice usually comes down to mess, frequency and cost rather than efficacy. Head-to-head trials show broadly comparable results for symptom relief.

Vaginal estradiol tablets or inserts (Vagifem, Yuvafem, Imvexxy). A small tablet or softgel inserted with an applicator. Loading phase is nightly for two weeks, then twice weekly. Least messy option. Available in 4 and 10 microgram doses.

Vaginal estradiol ring (Estring). A soft, flexible ring you insert and leave in place for 90 days. Releases about 7.5 micrograms daily. Best option if you want to think about it four times a year instead of twice a week. Not to be confused with Femring, which is a systemic-dose ring used for hot flashes.

Vaginal estrogen cream (Estrace, Premarin cream). Applied with an applicator, typically nightly for two weeks then two to three times weekly. Advantage: you can also apply a small amount externally to the vulva and vestibule, which is where a lot of the pain with intercourse actually originates. Disadvantage: messier, and dosing is less precise.

Vaginal DHEA (prasterone, Intrarosa). A nightly insert that is converted to estrogen and testosterone locally within the vaginal cells. Not an estrogen product itself, which makes it an option some oncologists are more comfortable with.

Ospemifene (Osphena). An oral selective estrogen receptor modulator taken daily. Acts as an estrogen agonist on vaginal tissue. Useful for women who cannot or will not use anything vaginally. Carries a small hot flash side effect and a systemic clot warning.

On cost: generic estradiol cream and generic vaginal tablets are frequently the cheapest routes, and prices vary enormously between insurance and cash-pay discount programs. It is worth asking for the generic specifically.

A practical add-on that is often skipped: a vaginal moisturizer used two to three times weekly (different from a lubricant, which is used only during sex) improves comfort while you wait for the estrogen to work, and is useful long-term alongside it.

Indefinitely, in most cases, and this surprises people.

Vaginal estrogen does not cure GSM. It treats it. The tissue responds while you are using it and reverts when you stop, usually within two to three months, because the underlying cause, low circulating estrogen, has not changed. Studies of discontinuation consistently show symptom return.

This is a different framing than systemic hormone therapy, where the conversation often centers on duration limits and periodic reassessment of risk versus benefit. With low-dose vaginal estrogen, the safety data does not support an arbitrary stop date. The Menopause Society's position is that treatment can continue as long as it is needed, with no requirement to taper off at a set number of years.

What should trigger a check-in with your clinician:

• •Any vaginal bleeding while on vaginal estrogen. This always warrants evaluation, regardless of how minor. Do not assume it is from the product.
• •No improvement by 12 weeks. GSM is common but not the only cause of vulvar pain. Lichen sclerosus, vulvodynia, pelvic floor dysfunction and dermatitis all present similarly and are frequently missed.
• •New urinary symptoms that do not respond, which may need separate urologic workup.

One more thing worth naming: pelvic floor physical therapy is dramatically underused for GSM-related pain. When tissue has been painful for a long time, the pelvic floor muscles guard and tighten in response. Fixing the tissue with estrogen without addressing the muscular pattern leaves many women still uncomfortable. If you have had pain with penetration for more than a year, ask for a referral alongside the prescription.

Sexual function in midlife is rarely a single-variable problem. Desire, arousal, tissue health and relationship context all interact, and we get into that in [libido in menopause](/blog/libido-and-intimacy-on-glp1-during-menopause) and in [testosterone for women](/blog/testosterone-for-women-in-menopause-what-the-evidence-shows).